



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/548,081	04/12/2000	Florencio Zaragoza Dorwald	5390.200-US	5691

7590 03/13/2003

Steve T Zelson Esq
Novo Nordisk of North America Inc
405 Lexington Ave
Suite 6400
New York, NY 10174-6401

EXAMINER

LIU, HONG

ART UNIT PAPER NUMBER

1624

DATE MAILED: 03/13/2003

16

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Applicati n No.

09/548,081

Applicant(s)

DORWALD ET AL.

Examiner

Hong Liu

Art Unit

1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on 03 February 2003.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☐ Claim(s) 102-132 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 102-109, 113, 116-124 and 129-132 is/are rejected.
- 7) ☒ Claim(s) 110-112, 114, 115 and 125-128 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____
- 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____

Art Unit: 1624

DETAILED ACTION

Claims 102-132 are pending in this application.

This action is in response to the applicants' amendment and reply filed on February 3, 2003.

Response to Arguments

Applicants' arguments filed on February 3, 2003 have been fully considered. Although applicants' amendment overcame the art rejection in the previous office action, the amendment necessitated the new ground(s) of rejection.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim Rejections - 35 USC § 102

Claims 102-109, 123, 124, 130-132 are rejected under 35 U.S.C. 102(b) as being anticipated by Arcari et al., Chem Abstract 80: 45767. The instantly claimed compounds read on the reference compound, see the enclosed copy of CAPLUS computer search report and the compound having RN 70651-72-8 and 70651-74-0.

Claim Rejections - 35 USC § 112

The rejection to claims under 35 U.S.C., 112, first paragraph, is hereby withdrawn in view of applicant's amendment and argument.

Claims 106-109, 113, 116-123, and 129 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The following reasons apply:

Art Unit: 1624

1) Claims 106 and 116-120 recite the limitation "R13" in Z. There is insufficient antecedent basis for this limitation in the claim.

2) Claims 107-108, 121, and 122 recite the limitation "cycloalkyl, cycloalkenyl" and "cyclopentyl, cyclohexyl, cyclohexenyl" in Z. There is insufficient antecedent basis for this limitation in the claim.

3). Claims 113 and 121 recite the limitation "adamanyl" and "oxazolyl" in Z. There is insufficient antecedent basis for this limitation in the claim.

4), Claim 109 depends on a canceled claim.

5). Claim 123 is a substantial duplicate of claim 109 if claim 109 actually depends on claim 102.

6). Claim 129 is of indeterminate scope for more than one reason. First, no one particular disorder is recited. Second, the claim language may read on diseases not yet fully understood to be associated with overweight and obesity. In addition, how does one determine who is "in need of such treatment" and who is not. Specification appears to give no guidance to the answer.

Claim Objections

Claims 110-112, 114, 115, and 125-128 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Conclusion

1. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).


Art Unit: 1624

2. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication should be directed to Examiner Hong Liu whose telephone number is (703) 306-5814. The examiner can normally be reached on Monday through Friday from 8:30 AM to 6:00 PM. If attempts to reach the examiner by the phone are unsuccessful, the examiner's supervisor, Mukund Shah can be reached at (703) 308-4716. The fax phone number for this group is (703) 308-4734 for "unofficial" purposes and the actual number for official business is (703) 308-4556. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose number is (703) 308-1235.

hl
March 13, 2003



Mukund Shah
Supervisory Patent Examiner
Art Unit 1624

JOHN M. FORD
PRIMARY EXAMINER
GROUP - ART UNIT 1624

Art Unit: 1624

DETAILED ACTION

Claims 102-132 are pending in this application.

This action is in response to the applicants' amendment and reply filed on February 3, 2003.

Response to Arguments

Applicants' arguments filed on February 3, 2003 have been fully considered. Although applicants' amendment overcame the art rejection in the previous office action, the amendment necessitated the new ground(s) of rejection.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim Rejections - 35 USC § 102

Claims 102-109, 123, 124, 130-132 are rejected under 35 U.S.C. 102(b) as being anticipated by Arcari et al., Chem Abstract 80: 45767. The instantly claimed compounds read on the reference compound, see the enclosed copy of CAPLUS computer search report and the compound having RN 70651-72-8 and 70651-74-0.

Claim Rejections - 35 USC § 112

The rejection to claims under 35 U.S.C., 112, first paragraph, is hereby withdrawn in view of applicant's amendment and argument.

Claims 106-109, 113, 116-123, and 129 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The following reasons apply: